Additional Actos indication for Takeda
Japan-based drugmaker Takeda has received an additional domestic indication, of concomitant type 2 diabetes therapy with biguanides, for its Actos (pioglitazone hydrochloride).
In a randomized, double-blind, comparative study, in which biguanides monotherapy was compared with Actos plus biguanides concomitant therapy, the latter showed a statistically-significant difference in improving glycemic control without increasing the risk of hypoglycemia.
Actos directly targets insulin resistance by improving sensitivity to insulin mainly in muscles, fat cells and the liver. Biguanides act primarily by reducing the amount of glucose produced by the liver. The drug is currently authorized for concomitant therapy with sulfonylurea or alpha-GI.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze